Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

(2020) Inju Cho et al.   BMC CANCER

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma

(2020) Matias Autio et al.   HAEMATOLOGICA

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

(2020) Sirpa Leppä et al.   Blood Advances

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program

(2019) Ling Li et al.   MODERN PATHOLOGY

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

(2019) Ziju Y. Xu-Monette et al.   Cancer Immunology Research

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype

(2019) James Godfrey et al.   BLOOD

Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist

(2019) Kevin W Ng et al.   eLife

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

(2019) Justin Kline et al.   BLOOD

Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer

(2018) Zehong Chen et al.   CANCER SCIENCE

High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2

(2018) Yanyan Li et al.   CANCER SCIENCE

Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients

(2018) Amro Mohamed Sedky El-Ghammaz et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

(2018) Bjoern Chapuy et al.   NATURE MEDICINE

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma

(2018) Suvi-Katri Leivonen et al.   HAEMATOLOGICA

Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma

(2018) Priscilla Brito da Silva et al.   HEMATOLOGICAL ONCOLOGY

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

(2018) S Ciavarella et al.   ANNALS OF ONCOLOGY

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

(2018) Boyang Chang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

(2018) Kathleen M. Mahoney et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Identification and characterization of an alternative cancer-derived PD-L1 splice variant

(2018) Nadia B. Hassounah et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

(2017) D Rossille et al.   LEUKEMIA

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

(2017) Stephan Kruger et al.   OncoImmunology

PD-1 expression on the surface of peripheral blood CD4+T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma

(2016) Wei Zhang et al.   Cancer Medicine

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

(2015) Colm Keane et al.   Lancet Haematology

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy

(2013) Colm Keane et al.   AMERICAN JOURNAL OF HEMATOLOGY

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

(2013) SR Greisen et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE

Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1

(2011) Mi-Young Song et al.   JOURNAL OF IMMUNOTHERAPY